Product name: Ciprofloxacin hydrochloride tablet
Specification: 250mg, 500mg, 750mg
Shelf Life: 3 Years
This product is mainly composed of ciprofloxacin hydrochloride. Its chemical name is: 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid hydrochloride monohydrate.
Molecular Formula: C17H18FN3O3·HCl·H2O
Molecular Weight: 385.82
This product is a film-coated tablet that is white to slightly yellow after removal of the coating.
Used for sensitive bacteria 
(1) Urogenital infections, including simple, complicated urinary tract infections, bacterial prostatitis, Neisseria gonorrhoeae urethritis, or cervicitis (including those produced by enzyme-producing strains).
(2) Respiratory tract infections, including acute bronchial infections and lung infections caused by sensitive gram-negative bacilli.
(3) Gastrointestinal tract infections caused by Shigella spp., Salmonella spp., Enterotoxin-producing Escherichia coli, Aeromonas hydrophila, and Vibrio parahaemolyticus.
(4) Typhoid fever.
(5) bone and joint infections.
(6) Skin and soft tissue infections.
(7) Systemic infections such as sepsis.
According to ciprofloxacin 0.25g
(1) Common dose for adults: 0.5 to 1.5g (2 to 6 tablets) per day, divided into 2 to 3 times.
(2) bone and joint infections: 1 ~ 1.5g (4 to 6 tablets) a day, 2 to 3 times, treatment for 4 to 6 weeks or longer.
(3) Pneumonia and skin and soft tissue infections: 1 to 1.5 g (4 to 6 tablets) a day, 2 to 3 times, 7 to 14 days of treatment.
(4) Intestinal tract infection: 1g (4 tablets) a day, divided into 2 times, and the course of treatment is 5 to 7 days.
(5) Typhoid: 1.5g (6 tablets) a day, divided into 2 to 3 times, the course of 10 to 14 days.
(6) Urinary tract infection: acute simple lower urinary tract infection, 0.5g (2 tablets) a day, 2 times service, treatment 5 to 7 days; complex urinary tract infection, day 1g (4), points 2 times, treatment 7 to 14 days.
(7) simple gonorrhea: a single oral 0.5g (2 tablets).
(1) Gastrointestinal reactions are more common and may manifest as abdominal discomfort or pain, diarrhea, nausea, or vomiting.
(2) The central nervous system may have dizziness, headache, lethargy or insomnia.
(3) Allergic reactions: Rash, pruritus, occasionally exudative erythema multiforme and angioneurotic edema. A few patients have photosensitivity reactions.
(4) Even happens:
1 seizures, mental disorders, irritability, confusion, hallucinations, tremors;
2 hematuria, fever, rash and other interstitial nephritis;
3 crystalline urine, more common in high-dose applications;
4 joint pain.
(5) A small number of patients may have elevated serum transaminases and blood urea nitrogen and decreased peripheral blood leukocytes, which are mostly mild and transient.
Disables allergy to this product and quinolones.
(1) Due to the current prevalence of E. coli resistance to fluoroquinolones, urine culture specimens should be taken prior to administration and adjusted for bacterial susceptibility results.
(2) This product should be taken on an empty stomach. Although the food can delay its absorption, its total absorption (bioavailability) has not been reduced, so it can also be taken after meals to reduce gastrointestinal reactions; .
(3) Crystalluria may occur when the product is used in large doses or when the urinary pH is above 7. In order to avoid the occurrence of crystalline urine, it is advisable to drink more water and maintain a urine output of 1200 ml or more for 24 hours.
(4) In patients with impaired renal function, the dosage should be adjusted according to renal function.
(5) Moderate and severe photosensitizing reactions can occur with fluoroquinolones. When using this product, excessive exposure to sunlight should be avoided. If photosensitized reaction occurs, it should be stopped.
(6) When liver function declines, if it is severe (cirrhosis of ascites) can reduce drug clearance, blood concentration increases, and liver and kidney function decline are particularly obvious, both need to weigh the advantages and disadvantages of the application, and adjust the dose.
(7) Patients with existing central nervous system disorders, such as epilepsy and epilepsy, should be avoided. The indications should be carefully weighed against the pros and cons.